One of India's top-Health policy makers and Niti-Aayog member Dr V K Paul has termed Novovax's Covid-19 vaccine's efficacy data as promising and has said that its trials in India are in an advanced stage of completion.
"What we're learning from data available in the public domain that this vaccine is very safe and highly effective. It'll be produced in India", Dr Paul has said, as quoted by Livemint.
The ICMR and SII are jointly performing a phase-2/3 observer-blind, randomised, controlled study to determine the safety and immunogenicity of Covovax in Indian adults.
It was reported yesterday (14 June) that the Novovax Covid-19 vaccine has shown 90 per cent efficacy in a late-stage study carried out in the US and Mexico and involved 30,000 participants.
Novovax's vaccine is easy to supply and store and is expected to play a key role in boosting vaccine supply in developing nations. It can be stored in standard refrigerators.
Novovax has entered in an agreement with Serum Institute of India (SII) to produce 1.1 billion doses of the vaccine. This will be the second vaccine produced by SII after Covishield.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.